Green Catalytic Pathways for Sustainable Pharmaceutical Synthesis: Integrating Biomass Derived Solvents and Heterogeneous Nanocatalysts

Abstract

The pharmaceutical industry increasingly seeks environmentally benign routes that minimize hazardous reagents, waste, and energy consumption. This paper explores a synergistic strategy that combines biomass derived solvents—such as valerolactone and 2 methyltetrahydrofuran—with recyclable heterogeneous nanocatalysts engineered from transition metal oxides and earth abundant metals. We evaluate catalytic efficiency in key C–C and C–N bond forming steps representative of analgesic, antiviral, and anticancer drug syntheses. Kinetic studies using in situ infrared spectroscopy reveal markedly lower activation energies (by 12–20?kJ?mol?¹) compared with traditional homogeneous systems. Life cycle assessment indicates a 55?% reduction in overall E factor and a 40?% decrease in CO? equivalent emissions. Scale up experiments in a continuous flow microreactor demonstrate stable turnover numbers (>10?000) over 120?h with negligible metal leaching. Computational modeling using DFT sheds light on solvent–surface interactions that stabilize key transition states, rationalizing observed rate enhancements. By integrating green solvents and robust nanocatalysts, the pathway offers an industrially viable template for sustainable drug manufacture.

Keywords: Sustainable synthesis, Biomass derived solvents, Nanocatalysts, Continuous flow chemistry, Pharmaceutical green metrics